MYM Shifts Focus in Australia

Cannabis Investing News
CSE:MYM

MYM Nutraceuticals Inc. (CSE:MYM) (“MYM” or “The Company”) announces that the Company is exploring other potential partnerships and will not be proceeding with the project with Australia-based Solaris Nutraceuticals and the proposed Casino, New South Wales, production facility.

MYM Nutraceuticals Inc. (CSE:MYM) (“MYM” or “The Company”) announces that the Company is exploring other potential partnerships and will not be proceeding with the project with Australia-based Solaris Nutraceuticals and the proposed Casino, New South Wales, production facility. In furtherance of this, Solaris is in the process of deregistering the company. The shareholders of Solaris, including MYM, determined that deregistration was the best way to move forward allowing MYM and others to pursue other exciting projects and opportunities in Australia.

“MYM determined based on the structure of the transaction and our minority interest in the Solaris deal, that it was not in our best interest to proceed with our current partners”, said Rob Gietl, CEO of MYM. “We are committed to becoming a global player and expanding our business into Australia. Our recent announcement stating we’ve entered into a conditional agreement with Sunmark Growth speaks to this fact. We believe that legalization barriers will be softened around the globe with Australia being a prime candidate for reform. MYM will be there when these changes occur to take full advantage of new business opportunities”.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and hemp. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD

Rob Gietl, CEO

MYM Nutraceuticals Inc.

www.mym.ca

Investor Relations

Brian Tasker

1.403.616.1045

brian.tasker@mym.ca

Keep up to date with MYM on our social media channels:

Twitter: @mymnutra

Facebook: @mymnutra

Instagram: @mymnutra

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Click here to connect with MYM Nutraceuticals Inc. (CSE:MYM) for an Investor Presentation. 

Source: www.thenewswire.com

The Conversation (0)
×